However, venetoclax is less effective than navitoclax (which targets both BCL-2 and BCL-XL) as a monotherapy in most ALL samples [28], with the notable exception of MLLr ALL leukemias 18, 28. This evidence concerns the gene BCL2L1 and leukemia.